Takeru Kashiwada
YOU?
Author Swipe
View article: Bortezomib induces Rho-dependent hyperpermeability of endothelial cells synergistically with inflammatory mediators
Bortezomib induces Rho-dependent hyperpermeability of endothelial cells synergistically with inflammatory mediators Open
View article: Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients
Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients Open
Background: Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs). Liquid biomarkers to predict irAE occurrence are urgently needed. We previously developed an ELISA system to specifically detect soluble PD-L…
View article: Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer
Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer Open
Background The tumor microenvironment (TME) impacts the therapeutic efficacy of immune checkpoint inhibitors (ICIs). No liquid biomarkers are available to evaluate TME heterogeneity. Here, we investigated the clinical significance of PD-1-…
View article: Clinical course of COPD patients with exercise-induced elevation of pulmonary artery pressure or less severe pulmonary hypertension presenting with respiratory symptoms and the impact of bosentan intervention—prospective, single-center, randomized, parallel-group study
Clinical course of COPD patients with exercise-induced elevation of pulmonary artery pressure or less severe pulmonary hypertension presenting with respiratory symptoms and the impact of bosentan intervention—prospective, single-center, randomized, parallel-group study Open
View article: Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients
Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients Open
BACKGROUND Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs). However, the biological mechanisms underlying irAEs are not well understood. We previously developed an ELISA system to specifically detect so…
View article: Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis
Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis Open
Everolimus-associated ILD is mild and has a favorable prognosis. Patients with symptomatic ILD were more likely to have higher SP-D levels than those with asymptomatic ILD. Granulomatous lesions are an important pathological feature of eve…
View article: Clinical significance of PD-1-binding soluble PD-L1 and MMPs in the microenvironment of gastric cancer and non-small cell lung cancer treated with PD-1/PD-L1 blockade
Clinical significance of PD-1-binding soluble PD-L1 and MMPs in the microenvironment of gastric cancer and non-small cell lung cancer treated with PD-1/PD-L1 blockade Open
Purpose The tumor microenvironment (TME) impacts the therapeutic efficacy of immune checkpoint inhibitors (ICIs). No liquid biomarkers are available to evaluate TME heterogeneity. Here, we investigated the clinical significance of PD-1-bin…
View article: Pulmonary Mycobacterium avium complex infection with vascular Ehlers–Danlos syndrome: A case report
Pulmonary Mycobacterium avium complex infection with vascular Ehlers–Danlos syndrome: A case report Open
View article: Additional file 1 of Identification of kynurenine and quinolinic acid as promising serum biomarkers for drug-induced interstitial lung diseases
Additional file 1 of Identification of kynurenine and quinolinic acid as promising serum biomarkers for drug-induced interstitial lung diseases Open
Additional file 1: Table S1. Raw data on biomarker concentrations and baseline characteristics of each DILD and DILD recovery sample. # Some samples could not be masured due to insufficient serum available for the quantitative analysis. Ta…
View article: Clinical course of COPD patients with exercise-induced elevation of pulmonary artery pressure or less severe pulmonary hypertension presenting with respiratory symptoms and the impact of bosentan intervention— prospective, single-center, randomized, parallel-group study
Clinical course of COPD patients with exercise-induced elevation of pulmonary artery pressure or less severe pulmonary hypertension presenting with respiratory symptoms and the impact of bosentan intervention— prospective, single-center, randomized, parallel-group study Open
Background: The data on bosentan were lacking for the treatment of exercise-induced elevation of pulmonary artery pressure (eePAP) or less severe PH in COPD. This study was conducted to investigate long-term efficacy and safety of bosentan…
View article: Kikuchi-Fujimoto disease can present as delayed lymphadenopathy after COVID-19 vaccination
Kikuchi-Fujimoto disease can present as delayed lymphadenopathy after COVID-19 vaccination Open
Following COVID-19 vaccination, ipsilateral axillary and cervical lymphadenopathy may occur, called vaccine-related hypermetabolic lymphadenopathy, which is considered reactive lymphadenopathy. We report here a case of Kikuchi-Fujimoto dis…
View article: P15‐7: Bosentan has potential benefits in patients with exercise OR mild‐to‐moderate pulmonary hypertension associated with COPD
P15‐7: Bosentan has potential benefits in patients with exercise OR mild‐to‐moderate pulmonary hypertension associated with COPD Open
View article: Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease Open
Background The role of inhaled corticosteroid (ICS) in chronic obstructive pulmonary disease (COPD) is unclear. Hence, this study aimed to evaluate the efficacy of ICS as an add-on to long-acting muscarinic antagonist (LAMA)/long-acting be…
View article: Stratifin as a Novel Diagnostic Biomarker in Serum for Diffuse Alveolar Damage
Stratifin as a Novel Diagnostic Biomarker in Serum for Diffuse Alveolar Damage Open
Among the various histopathological patterns of drug-induced interstitial lung disease (DILD), diffuse alveolar damage (DAD) is associated with poor prognosis. However, there is no reliable biomarker for its accurate diagnosis. Here, we sh…
View article: Detection of cardiac involvement in pulmonary sarcoidosis using high‐resolution Holter electrocardiogram
Detection of cardiac involvement in pulmonary sarcoidosis using high‐resolution Holter electrocardiogram Open
Background Early detection of cardiac involvement in patients with sarcoidosis is important but currently unresolved. The aim of this study was to elucidate the utility of frequency domain microvolt T‐wave alternans (TWA), signal‐averaged …
View article: A Possible, Non-Invasive Method of Measuring Dynamic Lung Compliance in Patients with Interstitial Lung Disease Using Photoplethysmography
A Possible, Non-Invasive Method of Measuring Dynamic Lung Compliance in Patients with Interstitial Lung Disease Using Photoplethysmography Open
Using photoplethysmography, we noted a significant reduction in Cdyn in patients with ILD. This novel non-invasive method is a promising tool for evaluating fibrosis progression in ILD.
View article: Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer
Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer Open
Osimertinib is the standard treatment for epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer. However, drug-induced interstitial lung disease (ILD) is recognized as a serious adverse event associated with EGFR-tyrosi…
View article: Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer
Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer Open
Background Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life‐threatening adverse event. The purpose of this study was to evaluate whether the development of immune‐related adverse events (…
View article: Exosome-Derived <i>microRNA</i>-<i>22</i> Ameliorates Pulmonary Fibrosis by Regulating Fibroblast-to-Myofibroblast Differentiation <i>in Vitro</i> and <i>in Vivo</i>
Exosome-Derived <i>microRNA</i>-<i>22</i> Ameliorates Pulmonary Fibrosis by Regulating Fibroblast-to-Myofibroblast Differentiation <i>in Vitro</i> and <i>in Vivo</i> Open
Exosomal miR-22 modulates fibroblast-to-myofibroblast differentiation. The present findings warrant further study, which could shed light on miR-22 as a novel therapeutic target in IPF.
View article: Interstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small cell lung cancer patients
Interstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small cell lung cancer patients Open
View article: Severe Pneumonitis with Alveolar Hemorrhage Associated with Herbal Medicines: A Case Report
Severe Pneumonitis with Alveolar Hemorrhage Associated with Herbal Medicines: A Case Report Open
We report a case of pneumonitis with alveolar hemorrhage induced by herbal medicines in a 73-year-old woman who was admitted to our hospital because of dyspnea and an abnormal shadow on a chest radiograph. She had received treatment with n…
View article: Spontaneous pulmonary hematoma with diffuse pulmonary ossification requiring emergency treatment: a case report
Spontaneous pulmonary hematoma with diffuse pulmonary ossification requiring emergency treatment: a case report Open
We report a case of spontaneous pulmonary hematoma with diffuse pulmonary ossification. Although the relationship between the two remains unclear, considering the possibility of appearance of new lesions/recurrence, we believe that careful…
View article: Organizing Pneumonia after Nivolumab Treatment in a Patient with Pathologically Proven Idiopathic Pulmonary Fibrosis
Organizing Pneumonia after Nivolumab Treatment in a Patient with Pathologically Proven Idiopathic Pulmonary Fibrosis Open
Acute exacerbation of pre-existing interstitial lung disease (ILD) associated with systemic anticancer therapy is recognized as a life-threatening adverse event of lung cancer treatment. Programmed cell death 1 (PD-1) checkpoint inhibitors…
View article: Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations
Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations Open
View article: Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis
Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis Open
An 82-year-old man with a recurrence of pulmonary pleomorphic carcinoma was treated with pembrolizumab. He achieved partial response after three cycles of pembrolizumab. However, he developed febrile neutropenia. A bone marrow aspiration s…
View article: A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab Open
We herein describe the case of a 67-year-old woman with advanced lung adenocarcinoma who developed interstitial lung disease (ILD) with alveolar hemorrhage induced by pembrolizumab. She received four courses of pembrolizumab therapy and ac…
View article: Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression Open
Immuno-checkpoint inhibitors (ICI) have become an effective treatment option for non-small-cell lung cancer patients. However, ICI therapy was reported to be less effective in patients with epidermal growth factor receptor (EGFR) mutations…
View article: Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation
Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation Open
View article: Pulmonary embolism and deep vein thrombosis in eosinophilic granulomatosis with polyangiitis successfully treated with rivaroxaban
Pulmonary embolism and deep vein thrombosis in eosinophilic granulomatosis with polyangiitis successfully treated with rivaroxaban Open
View article: Prognostic Factors in the Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Retrospective Single-center Study
Prognostic Factors in the Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Retrospective Single-center Study Open
Objectives Acute exacerbation of idiopathic pulmonary fibrosis (IPF-AE) has been recognized as a fatal pulmonary disorder, but the exact prognostic factors are unknown. The aim of the present study was to analyze the clinical characteristi…